Literature DB >> 21952584

Dietary energy balance modulates prostate cancer progression in Hi-Myc mice.

Jorge Blando1, Tricia Moore, Stephen Hursting, Guiyu Jiang, Achinto Saha, Linda Beltran, Jianjun Shen, John Repass, Sara Strom, John DiGiovanni.   

Abstract

Male Hi-Myc mice were placed on three dietary regimens [30% calorie restriction (CR), overweight control (modified AIN76A with 10 kcal% fat), and a diet-induced obesity regimen (DIO) 60 kcal% fat]. All diet groups had approximately similar incidence of hyperplasia and low-grade prostatic intraepithelial neoplasia in the ventral prostate at 3 and 6 months of age. However, 30% CR significantly reduced the incidence of in situ adenocarcinomas at 3 months compared with the DIO group and at 6 months compared with both the overweight control and DIO groups. Furthermore, the DIO regimen significantly increased the incidence of adenocarcinoma with aggressive stromal invasion, as compared with the overweight control group (96% vs. 65%, respectively; P = 0.02) at the 6-month time point. In addition, at both 3 and 6 months, only in situ carcinomas were observed in mice maintained on the 30% CR diet. Relative to overweight control, DIO increased whereas 30% CR reduced activation of Akt, mTORC1, STAT3, and NFκB (p65) in ventral prostate. DIO also significantly increased (and 30% CR decreased) numbers of T-lymphocytes and macrophages in the ventral prostate compared with overweight control. The mRNA levels for interleukin (IL) 1α, IL1β, IL6, IL7, IL23, IL27, NFκB1 (p50), TNFα, and VEGF family members were significantly increased in the ventral prostate of the DIO group compared with both the overweight control and 30% CR diet groups. Collectively, these findings suggest that enhanced growth factor (Akt/mTORC1 and STAT3) and inflammatory (NFκB and cytokines) signaling may play a role in dietary energy balance effects on prostate cancer progression in Hi-Myc mice. 2011 AACR

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21952584      PMCID: PMC4171652          DOI: 10.1158/1940-6207.CAPR-11-0182

Source DB:  PubMed          Journal:  Cancer Prev Res (Phila)        ISSN: 1940-6215


  64 in total

1.  Risk factors for prostate cancer incidence and progression in the health professionals follow-up study.

Authors:  Edward Giovannucci; Yan Liu; Elizabeth A Platz; Meir J Stampfer; Walter C Willett
Journal:  Int J Cancer       Date:  2007-10-01       Impact factor: 7.396

2.  Comparisons of diets used in animal models of high-fat feeding.

Authors:  Craig H Warden; Janis S Fisler
Journal:  Cell Metab       Date:  2008-04       Impact factor: 27.287

3.  Nuclear localization of nuclear factor-kappaB p65 in primary prostate tumors is highly predictive of pelvic lymph node metastases.

Authors:  Laurent Lessard; Pierre I Karakiewicz; Pascale Bellon-Gagnon; Mona Alam-Fahmy; Hazem A Ismail; Anne-Marie Mes-Masson; Fred Saad
Journal:  Clin Cancer Res       Date:  2006-10-01       Impact factor: 12.531

4.  Extreme obesity reduces bone mineral density: complementary evidence from mice and women.

Authors:  Nomelí P Núñez; Catherine L Carpenter; Susan N Perkins; David Berrigan; S Victoria Jaque; Sue Ann Ingles; Leslie Bernstein; Michele R Forman; J Carl Barrett; Stephen D Hursting
Journal:  Obesity (Silver Spring)       Date:  2007-08       Impact factor: 5.002

5.  Low-carbohydrate diet versus caloric restriction: effects on weight loss, hormones, and colon tumor growth in obese mice.

Authors:  Karrie E Wheatley; Elizabeth A Williams; Nicole C P Smith; Alice Dillard; Eun Young Park; Nomeli P Nunez; Stephen D Hursting; Michelle A Lane
Journal:  Nutr Cancer       Date:  2008       Impact factor: 2.900

6.  Stat3 promotes metastatic progression of prostate cancer.

Authors:  Junaid Abdulghani; Lei Gu; Ayush Dagvadorj; Jacqueline Lutz; Benjamin Leiby; Gloria Bonuccelli; Michael P Lisanti; Tobias Zellweger; Kalle Alanen; Tuomas Mirtti; Tapio Visakorpi; Lukas Bubendorf; Marja T Nevalainen
Journal:  Am J Pathol       Date:  2008-05-15       Impact factor: 4.307

7.  Effect of low-fat diet on development of prostate cancer and Akt phosphorylation in the Hi-Myc transgenic mouse model.

Authors:  Naoko Kobayashi; R James Barnard; Jonathan Said; Jenny Hong-Gonzalez; Dan M Corman; Melvin Ku; Ngan Bao Doan; Dorina Gui; David Elashoff; Pinchas Cohen; William J Aronson
Journal:  Cancer Res       Date:  2008-04-15       Impact factor: 12.701

Review 8.  High-fat diets: modeling the metabolic disorders of human obesity in rodents.

Authors:  Roland Buettner; Jürgen Schölmerich; L Cornelius Bollheimer
Journal:  Obesity (Silver Spring)       Date:  2007-04       Impact factor: 5.002

9.  Saturated fat intake predicts biochemical failure after prostatectomy.

Authors:  Sara S Strom; Yuko Yamamura; Michele R Forman; Curtis A Pettaway; Stephanie L Barrera; John DiGiovanni
Journal:  Int J Cancer       Date:  2008-06-01       Impact factor: 7.396

10.  Pten dose dictates cancer progression in the prostate.

Authors:  Lloyd C Trotman; Masaru Niki; Zohar A Dotan; Jason A Koutcher; Antonio Di Cristofano; Andrew Xiao; Alan S Khoo; Pradip Roy-Burman; Norman M Greenberg; Terry Van Dyke; Carlos Cordon-Cardo; Pier Paolo Pandolfi
Journal:  PLoS Biol       Date:  2003-10-27       Impact factor: 8.029

View more
  38 in total

1.  A diagnosis of prostate cancer and pursuit of active surveillance is not followed by weight loss: potential for a teachable moment.

Authors:  M A Liss; J M Schenk; A V Faino; L F Newcomb; H Boyer; J D Brooks; P R Carroll; A Dash; M D Fabrizio; M E Gleave; P S Nelson; M L Neuhouser; J T Wei; Y Zheng; J L Wright; D W Lin; I M Thompson
Journal:  Prostate Cancer Prostatic Dis       Date:  2016-07-19       Impact factor: 5.554

2.  Effect of Metformin, Rapamycin, and Their Combination on Growth and Progression of Prostate Tumors in HiMyc Mice.

Authors:  Achinto Saha; Jorge Blando; Lisa Tremmel; John DiGiovanni
Journal:  Cancer Prev Res (Phila)       Date:  2015-04-23

3.  mTOR inhibitors for treatment of low-risk prostate cancer.

Authors:  Michael A Liss; Lanette Rickborn; John DiGiovanni; Dean Bacich; Linda A DeGraffenried; Manish Parihar; Ian M Thompson; Zelton Dave Sharp
Journal:  Med Hypotheses       Date:  2018-06-05       Impact factor: 1.538

4.  Suppression of prostate epithelial proliferation and intraprostatic progrowth signaling in transgenic mice by a new energy restriction-mimetic agent.

Authors:  Lisa D Berman-Booty; Po-Chen Chu; Jennifer M Thomas-Ahner; Brad Bolon; Dasheng Wang; Tiffany Yang; Steven K Clinton; Samuel K Kulp; Ching-Shih Chen
Journal:  Cancer Prev Res (Phila)       Date:  2012-12-28

Review 5.  Metabolic Vulnerabilities of Prostate Cancer: Diagnostic and Therapeutic Opportunities.

Authors:  Giorgia Zadra; Massimo Loda
Journal:  Cold Spring Harb Perspect Med       Date:  2018-10-01       Impact factor: 6.915

Review 6.  Obesity and cancer: mechanistic insights from transdisciplinary studies.

Authors:  Emma H Allott; Stephen D Hursting
Journal:  Endocr Relat Cancer       Date:  2015-09-15       Impact factor: 5.678

7.  Energy balance modulates mouse skin tumor promotion through altered IGF-1R and EGFR crosstalk.

Authors:  Tricia Moore; Linda Beltran; Steve Carbajal; Stephen D Hursting; John DiGiovanni
Journal:  Cancer Prev Res (Phila)       Date:  2012-08-15

Review 8.  Optimizing mouse models for precision cancer prevention.

Authors:  Clémentine Le Magnen; Aditya Dutta; Cory Abate-Shen
Journal:  Nat Rev Cancer       Date:  2016-02-19       Impact factor: 60.716

9.  OSU-CG5, a novel energy restriction mimetic agent, targets human colorectal cancer cells in vitro.

Authors:  El-shaimaa A Arafa; Ahmed H Abdelazeem; Hany H Arab; Hany A Omar
Journal:  Acta Pharmacol Sin       Date:  2014-01-27       Impact factor: 6.150

Review 10.  Obesity and prostate cancer: weighing the evidence.

Authors:  Emma H Allott; Elizabeth M Masko; Stephen J Freedland
Journal:  Eur Urol       Date:  2012-11-15       Impact factor: 20.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.